Company Overview
Champions Oncology, Inc. operates as a technology-enabled research company dedicated to providing specialized technology solutions for drug discovery and development within the United States. Through its proprietary Tumorgraft technology platform, the firm delivers personalized cancer care by facilitating the implantation of human tumors in immune-deficient models to advance oncological research. The company functions within the healthcare sector, specifically the biotechnology industry, an environment characterized by high innovation requirements and significant regulatory oversight regarding therapeutic development. Currently, the entity employs 213 individuals and holds a market capitalization of $79.71M, while generating annual revenue of $57.95M. These financial figures indicate that the company maintains a mid-sized position in the biotechnology landscape, possessing sufficient revenue streams to sustain operations despite the capital-intensive nature of drug discovery activities.
Financial Health
The company reported revenue of $57.95M over the trailing twelve months, accompanied by a net income of -$2,343,000 and an EBITDA of -$772,000. The substantial gap between the positive revenue figure and the negative net income reveals a cost structure where operating expenses significantly exceed gross profits, a common characteristic in early-stage biotechnology firms focusing on research and development. Despite the reported net loss, the company generated positive free cash flow of $4.70M, which provides essential financial flexibility to fund ongoing research programs without immediate reliance on external financing. The gross margin stands at 45.9%, indicating that the company retains a significant portion of revenue after accounting for the direct costs of generating its cancer care solutions. However, the operating margin is -1.1% and the profit margin is -4.0%, reflecting high overhead costs relative to sales and confirming that the company is not yet profitable on an operational basis. The balance sheet shows cash holdings of $7.13M against total debt of $5.00M, with a debt-to-equity ratio of 114.19%, suggesting a leveraged capital structure where debt exceeds equity. The current ratio of 0.98 indicates that current liabilities slightly exceed current assets, signaling potential constraints in short-term liquidity that require careful management of working capital. Furthermore, the return on equity is -47.6% and the return on assets is -4.7%, metrics that reveal that management has not yet generated positive returns on shareholder investments or the asset base utilized for operations.
Valuation Assessment
Valuation metrics for Champions Oncology, Inc. present a trailing P/E ratio that is not applicable due to negative earnings, while the forward P/E is calculated at 57.40. The disparity between the unavailable trailing P/E and the high forward P/E implies that the market prices in significant expected earnings improvement in the future, anticipating a turnaround from current losses. The price-to-book ratio is 18.64, which indicates a substantial market premium over the company's book value, reflecting investor confidence in the intangible value of its technology platform and future drug discovery pipeline. Alternative valuation metrics include a price-to-sales ratio of 1.38 and an EV/EBITDA of -100.62, suggesting that investors are valuing the company based on revenue potential rather than current profitability or earnings power. The stock has traded between a 52-week high of $9.97 and a 52-week low of $5.50, with the current price trading within the lower half of this established range. The beta value is 0.40, which means the stock exhibits lower price volatility relative to the broader market, moving less dramatically than the overall index during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year is -2.8%, while earnings growth is not applicable due to the company's negative earnings position. Since earnings growth is not applicable, it is not possible to determine if earnings are growing faster or slower than revenue, but the negative revenue growth indicates a contraction in top-line sales that must be addressed to achieve profitability. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, meaning the entity reinvests all available cash flows into research, development, and operational growth rather than distributing income to shareholders. The overall growth and income profile is characterized by a revenue contraction and an absence of dividend income, with the company's financial strategy focused entirely on expanding its technology-enabled research capabilities and achieving future profitability through its Tumorgraft platform.